218 related articles for article (PubMed ID: 19816937)
1. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
[TBL] [Abstract][Full Text] [Related]
2. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.
Decrausaz L; Domingos-Pereira S; Duc M; Bobst M; Romero P; Schiller JT; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 Aug; 129(3):762-72. PubMed ID: 21384340
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
4. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
5. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
6. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
8. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
12. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
[TBL] [Abstract][Full Text] [Related]
13. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
14. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
15. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
[TBL] [Abstract][Full Text] [Related]
16. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
17. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
[TBL] [Abstract][Full Text] [Related]
18. A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers.
Decrausaz L; Gonçalves AR; Domingos-Pereira S; Pythoud C; Stehle JC; Schiller J; Jichlinski P; Nardelli-Haefliger D
Int J Cancer; 2011 May; 128(9):2105-13. PubMed ID: 20635385
[TBL] [Abstract][Full Text] [Related]
19. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
[TBL] [Abstract][Full Text] [Related]
20. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
